

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Application Number	10/808,699
Filing Date	March 24, 2004
First Named Inventor	Marian Nakada
Group Art Unit	1644
Examiner Name	
Attorney Docket Number	CEN 5017USNP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Maher Haddad/	Date Considered	06/22/2006
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Application Number	10/808,699
Filing Date	MARCH 24, 2004
First Named Inventor	MARIAN NAKADA
Group Art Unit	1644
Examiner Name	
Attorney Docket Number	CEN5017USNP

[illegible]

Examiner Signature	/Maher Haddad/	Date Considered	06/22/2006
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Application Number	10/808,699
Filing Date	MARCH 24, 2004
First Named Inventor	NAKADA
Group Art Unit	5898
Examiner Name	HADDAD, MAHER M
Attorney Docket Number	CEN 5017USNP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
MH		BIWAS ET AL, "The Human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily." CANCER RES., 1995, pp 434-439, Vol. 55.	
MH		COUSSENS ET AL, "Matrix metalloproteinase inhibitors and cancer: trials and tribulations." SCIENCE, 2002, pp 2387-2392, VOL. 295.	
MH		DERYUGINA ET AL, "Up-regulation of vascular endothelial growth factor by membrane-type 1 matrix metalloproteinase stimulates human glioma xenograft growth and angiogenesis." CANCER RES., 2002, pp 580-588, Vol. 62.	
MH		ELLIS ET AL, "Monoclonal antibody preparation and purification of a tumor cell collagenase-stimulatory factor." CANCER RES., 1989, pp 3385-3391, VOL. 49.	
MH		FOLKMAN ET AL, "Angiogenesis in cancer, vascular, rheumatoid and other disease," NAT MED, 1995, pp 27-31, Vol. 1.	
MH		GUO ET AL, "Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells." J. BIOL CHEM, 1997, pp 24-27, VOL. 272.	
MH		HESLOP ET AL, "Response of steroid-resistant graft-versus-host disease to lymphoblast antibody CBL1." Lancet, 1995, pp 805-806, VOL. 346.	
MH		JAVADPOUR ET AL, "Tumor collagenase-stimulating factor and tumor autocrine motility factor as tumor markers in bladder cancer - an update," EUR UROL, 1992, pp Suppl 1:1-4, Vol. 21.	
MH		KATAOKA ET AL, "Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase." CANCER RES, 1993, pp 3154-3158, Vol. 53.	
MH		KLAGSBRUN ET AL, "Molecular angiogenesis," CHEM BIOL, 1999, R217-24, Vol. 6.	
MH		KOCH ET AL, "T cell activation-associated epitopes of C147 in regulation of the T cell response and their definition by antibody affinity and antigen density." INTERNAT. IMMUNOL., 1999, pp 777-786, Vol. 11.	
MH		MURAOKA ET AL, "Enhanced expression of a tumor-cell-derived collagenase-stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers," INT J CANCER, 1993, pp 19-26, Vol. 55.	
MH		POLETTE ET AL, "Tumor collagenase stimulatory factor (TCSF) expression and localization in human lung and breast cancers," J HISTOCHEM CYTOCHEM, 1997, pp 703-709, Vol. 45.	
MH		SAMESHIMA ET AL, "Expression of EMMPRIN (CD147), a cell surface inducer of matrix metalloproteinases, in normal human brain and gliomas," INT J CANCER, 2000a, pp 21-27, Vol. 88.	
MH		SAMESHIMA ET AL, "Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts." CANCER LETT, 2000b, pp 177-184, Vol. 157.	
MH		SOUNNI ET AL, "MT1-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression," FASEB J, 2002, pp 5550564, Vol. 16.	
MH		STAFFLER ET AL, "Selective inhibition of T cell activation via CD 147 through novel	

07/10/2006

/Maher Haddad/

 Cont.

		modulation of lipid rafts," J. IMMUNOL., 2003, pp 1707-1714, Vol. 171.	
MH		TANG ET AL, "Tumor-stroma interaction: Positive feedback of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN," MOL. CANCER RES., 2004, pp 73-80, VOL. 2.	
		ZUCKER ET AL, "Tumorigenic potential of extracellular matrix metalloproteinase inducer," AM J PATHOL., 2001, pp 1921-1926, Vol. 150.	
		US2003/0027161 (Dejardin et al) 6 FEBRUARY 2003 (06.02.2003), see paragraph 1139.	
		ZUCKER S. "Tumor cell-stromal cell interactions in cancer. Grant application from the Department of Veterans Affairs 24 August 2000 (24.08.2000).	
		LOOKSMART, EMMPRIN. Its role in tumor angiogenesis and metastasis. 2001, page 1.	
		ZUCKER ET AL. "Extracellular matrix metalloproteinase inducer (EMMPRIN) facilitates tumor angiogenesis. Proceedings of the American Association for Cancer Research Annual Meeting. (March 1998), Vol. 89, pp 41.	
		SAMESHIMA et al. Glioma cell extracellular matrix metalloproteinase inducer (EMMPRIN) (CD147) stimulates production of membrane-type matrix metalloproteinases and activated gelatinase A in co-cultures with brain-derived fibroblasts. Cancer Lett. 1 September 2000 (01.09.2000) Vol. 157, No. 2, pp 177-184.	
		ZUCKER ET AL, "Tumorigenic potential of extracellular matrix metalloproteinase inducer. Am. J. Pathol. 2001, Vol. 150, No. 6, pp 1921-1926.	

Examiner Signature	/Maher Haddad/	Date Considered	07/10/2006
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

